George Yancopoulos - Mar 23, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Signature
/s/** George D. Yancopoulos
Stock symbol
REGN
Transactions as of
Mar 23, 2023
Transactions value $
-$2,940,374
Form type
4
Date filed
3/27/2023, 04:41 PM
Previous filing
Feb 8, 2023
Next filing
Dec 13, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Sale -$203K -254 -0.13% $800.59 200K Mar 23, 2023 By Trust for Chldn. F1, F2, F3
transaction REGN Common Stock Sale -$97.7K -122 -0.06% $801.16 200K Mar 23, 2023 By Trust for Chldn. F1, F3, F4
transaction REGN Common Stock Sale -$993K -1.24K -0.62% $802.54 199K Mar 23, 2023 By Trust for Chldn. F1, F3, F5
transaction REGN Common Stock Sale -$516K -642 -0.32% $803.30 198K Mar 23, 2023 By Trust for Chldn. F1, F3, F6
transaction REGN Common Stock Sale -$204K -254 -0.13% $804.38 198K Mar 23, 2023 By Trust for Chldn. F1, F3, F7
transaction REGN Common Stock Sale -$37.9K -47 -0.02% $805.55 198K Mar 23, 2023 By Trust for Chldn. F1, F3
transaction REGN Common Stock Sale -$565K -700 -0.35% $806.47 197K Mar 23, 2023 By Trust for Chldn. F1, F3
transaction REGN Common Stock Sale -$324K -400 -0.2% $810.30 197K Mar 23, 2023 By Trust for Chldn. F1, F3
holding REGN Common Stock 570K Mar 23, 2023 Direct
holding REGN Common Stock 5.87K Mar 23, 2023 By 401(k) Plan
holding REGN Common Stock 200K Mar 23, 2023 by 2022 GRAT I
holding REGN Common Stock 250K Mar 23, 2023 by 2022 GRAT II
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to plans intended to comply with Rule 10b5-1(c) adopted on November 29, 2022.
F2 Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $800.52 to $800.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.
F3 As investment trustee of trusts for the benefit of the reporting person's children.
F4 Represents volume-weighted average price of sales of 122 shares of Company stock on March 23, 2023 at prices ranging from $801.00 to $801.92. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.
F5 Represents volume-weighted average price of sales of 1,237 shares of Company stock on March 23, 2023 at prices ranging from $802.00 to $802.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.
F6 Represents volume-weighted average price of sales of 642 shares of Company stock on March 23, 2023 at prices ranging from $803.01 to $803.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.
F7 Represents volume-weighted average price of sales of 254 shares of Company stock on March 23, 2023 at prices ranging from $804.00 to $804.77. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on March 23, 2023 at each separate price.